China's Hansoh ​Pharmaceutical said on Monday its ‌units have entered into a partnership and licensing deal with Roche, potentially worth more than $15 ​billion, that covers a portfolio of antibody-drug ​conjugate programs.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in